IP Library Granted Patent US 9,675,677
Granted Patent B2
US 9,675,677 · App. 14/931,682 · Granted Jun 13, 2017

Treatment of Peyronie's disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,675,677
App. No.
14/931,682
Granted
Jun 13, 2017
Kind
B2
Abstract

The invention relates to systems and therapeutic methods to reduce plaque causing Peyronie's disease. One approach uses high pressure injection of collagenase-containing composition into a penile plaque. Plaque disruption is enhanced by the mechanical force of the high pressure, followed by the enzymatic action of collagenase. Another approach uses collagenase as a pretreatment, followed by addition of adipose-derived stem cells ADSCs. The initial collagenase injection breaks down collagen (often more type III than type I in Peyronie's) to provide short term benefit. The longer-term benefit is provided by introduction of ADSCs to the plaque, which can produce cytokines and other signals for revascularization, and restoration of normal penile tissue. The resulting combination advantageously reduces the bulk of the plaque early on with ongoing reduction through the revascularization of the tissue. In addition, the treatment provides an advantageous shift of elastin and collagen ratios.

Claims (16)

1. A method for treating Peyronie's disease comprising:

(a) delivering a first composition comprising collagenase to a plaque in penile tissue, and

(b) delivering a second composition comprising adipose-derived stem cells to the plaque or an area of the penile tissue where the plaque existed,

wherein the first composition is delivered to the plaque using an injection device having a distal end with a plurality of needles that extend from the distal end of the injection device.

2. The method of claim 1 , where the collagenase is delivered before the stem cells.

3. The method of claim 1 , wherein collagenase in an amount of 1×10 4 to about 4×10 4 ABC units is delivered.

4. The method of claim 1 , wherein the first composition is delivered in a volume of 0.1 mL to about 1 mL.

5. The method of claim 1 where the plurality of needles includes at least one needle having multiple apertures.

6. The method of claim 1 where the first composition is delivered to the plaque using a plurality of pulses.

7. The method of claim 1 wherein the collagenase is delivered to the plaque using an injection pressure of at least 100 psi.

8. The method of claim 1 wherein the collagenase is delivered to the plaque using an injection pressure in the range of 140 psi to 2000 psi.

9. The method of claim 1 , wherein composition comprising adipose-derived stem cells is delivered in an amount in the range of 0.1 mL to about 1 mL.

10. The method of claim 1 , wherein the adipose-derived stem cells are mixed with an adipose tissue derived cell matrix material to prepare the second composition comprising adipose-derived stem cells.

11. A method for treating Peyronie's disease comprising a step of delivering a composition comprising collagenase to a plaque in penile tissue using an injection pressure of at least 100 psi,

wherein the composition is delivered to the plaque using an injection device having a distal end with a plurality of needles that extend from the distal end of the injection device.

12. The method of claim 11 comprising steps of: (a) obtaining an adipose tissue sample from a patient with Peyronie's disease; (b) preparing an adipose stem cell composition enriched for adipose-derived stem cells from a portion of the adipose tissue sample; (c) preparing a cell injection composition comprising the substeps of mixing the adipose stem cell composition with a mechanically-processed portion of the adipose tissue; (d) delivering the composition comprising collagenase to the plaque in penile tissue using the injection pressure of at least 100 psi, and, after step (d), (e) delivering the cell injection composition to the plaque or an area of the penile tissue where the plaque existed.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2017
From: AMERICAN MEDICAL SYSTEMS, LLC
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 044581/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2017
From: AMS RESEARCH, LLC
To: AMERICAN MEDICAL SYSTEMS, LLC
Reel/Frame 044581/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: BORGOS, NATALIE ANN
To: AMS RESEARCH CORPORATION
Reel/Frame 042251/0336 →
CHANGE OF NAME Recorded May 5, 2017
From: AMS RESEARCH CORPORATION
To: AMS RESEARCH, LLC
Reel/Frame 042415/0542 →